Is Your ED A Symptom Of Something Deadly? The Truth About Heart & Hormone Health - Roundtable #210

The panel challenged the 300 ng/dL cutoff as logically inconsistent when the AUA's own treatment target is 450-600 ng/dL. If the goal is to get men into the 450-600 range, then a man at 390 ng/dL who feels terrible should logically be treated to reach that range. The rigid adherence to 300 ng/dL as a treatment threshold creates a paradox where a man must drop below the therapeutic target before qualifying for treatment to reach that same target. One panelist noted that clinical experience over decades shifts a physician's comfort: early-career clinicians are number-bound; later-career clinicians treat the patient. The problem is that most frontline prescribers (primary care) lack the volume of experience to develop this comfort and therefore undertreat. The recommendation is that patients should seek second opinions when denied treatment based on borderline numbers, and that clinicians should consider a 3-month therapeutic trial as a diagnostic test — if the patient improves, the diagnosis is confirmed.

The panel emphasized that ED is uniquely valuable as a screening gateway because men who avoid healthcare for decades will immediately seek care for erections. One panelist noted the 'desert of men's healthcare' — girls are handed off to OB/GYNs at menarche, but boys have no analogous transition point and often go 20 years without seeing a physician. ED provides that entry point. The panel described the typical inadequate primary care encounter: a man says his erections are 'not as good as they used to be,' receives Viagra, and is sent out — with undiagnosed hypertension, hyperlipidemia, and insulin resistance festering for another decade. The paradigm shift is to view ED as a symptom requiring differential diagnosis (depression, cardiovascular disease, diabetes, prostate cancer, hypogonadism) rather than a disease treated with PDE5 inhibitors.

The bidirectional relationship between obesity and testosterone is characterized as a 'feed-forward cycle': more fat → more aromatization → less testosterone → less energy and muscle mass → more fat accumulation. Breaking this cycle by cutting 10% weight creates an opposite positive cycle: more testosterone available for muscle, energy, and libido, facilitating further gains. The panel discussed GLP-1 agonists as a new tool that produces sustainable weight loss (unlike previous interventions where 95% of diets failed and weight was regained). However, they noted the emerging issue of sarcopenia with GLP-1 agonists — up to 30% of weight lost can be muscle — and discussed the rationale for combining testosterone with GLP-1 agonists to preserve lean mass. New companies are specifically developing GLP-1/SARM or GLP-1/testosterone combinations for this purpose.

The panel noted that testicular self-examination education is almost entirely absent from men's health interactions. Unlike women who are taught breast self-examination and transitioned to gynecologic care at menarche, men have no corresponding touchpoint. One panelist described seeing men whose 'whole testicles are replaced by cancer because they just don't know or refuse to face the fact that something bad' is happening. The tactile teaching aid — comparing to knuckles vs between-knuckles — provides a simple, memorable self-screening tool that requires no equipment. Testicular hypotrophy (one testicle shrinking relative to its previous size or the contralateral side) can also signal pathology including varicocele-induced damage.

The panel discussed CAG repeats as one of two mechanisms by which men may need more testosterone: receptor insensitivity (CAG repeats) or increased metabolic clearance/metabolism (obesity, certain genetic variants in SHBG or aromatase). The test was pioneered at Baylor College of Medicine and remains standard in their workup. It explains a significant portion of the inter-individual variability in symptomatic response to a given serum testosterone level. The panel explicitly separated this from the obesity-driven need for higher dosing, which is due to increased aromatization and suppressed pituitary function rather than receptor-level issues.

The panel discussed the emergence of GLP-1 agonists as a major treatment for obesity and their secondary benefit of raising testosterone through weight loss. However, they raised concern about muscle loss: severe caloric restriction (whether through GLP-1 agonists or starvation) causes catabolism of lean tissue. Sleep deprivation during weight loss preferentially shunts lost weight toward muscle rather than fat, making sleep a critical co-intervention. Some companies are now developing combined GLP-1/SARM or GLP-1/testosterone products specifically to address this sarcopenia risk. The panel also noted that GLP-1 agonists produce sustainable weight loss in a way previous interventions could not — most diets fail (95%), but patients on maintenance GLP-1 dosing maintain their losses. This sustainability is what enables the testosterone benefit to persist.

The panel described onco-TESE as a subspecialty technique: during orchiectomy, the surgeon works with the pathologist who maps the cancer location, identifies healthy testicular parenchyma, and the surgeon extracts that healthy tissue for sperm extraction and cryopreservation. The cancerous tissue then goes to pathology for staging. This is part of the broader field of oncofertility, which exists for both men and women (ovarian cryopreservation, ovarian transposition out of radiation fields). The panel noted that major cancer centers (MD Anderson was mentioned) have dedicated oncofertility staff, though services have historically focused more on women. The essential message: a cancer diagnosis does not preclude discussing fertility, and fertility preservation must be addressed before, not after, treatment.

One panelist, who has performed thousands of vasectomies and trained over 130 fellows in the technique, emphasized that vasectomy must be presented as permanent during consent, even though reversal is possible. The reality is that most urologists do not perform reversals because they lack the patient volume and specific microsurgical training. The distinction between vasovasostomy (reconnecting the vas deferens) and epididymovasostomy (connecting the vas to the epididymis, needed when back-pressure has caused epididymal blowout) is critical — the latter is technically more demanding and the decision is made intraoperatively based on vasal fluid examination. High-volume centers can make and execute this decision appropriately.

The TRAVERSE trial used a topical testosterone gel formulation and measured testosterone at trough levels (average increase of 147 ng/dL over placebo). Critics note that injection-based therapy produces higher peaks and greater erythrocytosis, so the cardiovascular safety data from TRAVERSE may not perfectly translate to injectable testosterone. The FDA's decision came exactly 10 years after the original warning was imposed, and the principal investigators experienced a two-year silence between initial publication of safety data in 2023 and the FDA's final decision in 2025. The speaker called this moment 'huge' and recalled exactly where he was when the announcement appeared on his feed.

The speaker presented a startling statistic: a 35-year-old man presenting with ED today has a 15% chance of having a heart attack or stroke within 7 years. He is also 3.5 times more likely to suffer from clinical depression, and there is a 30% chance he has undiagnosed diabetes or prediabetes. If these conditions go undetected and are only discovered 5-10 years later when frank disease develops, the intervening years represent ongoing vascular damage that could have been mitigated. The speaker argues that ED serves as a unique gateway to men's health precisely because men who would never go to a doctor for blood pressure screening will immediately seek care for erectile problems. Even psychogenic ED — where Doppler ultrasound shows normal blood flow but anxiety impairs erections — is now associated with more heart attacks, possibly because the daily anticipation of sexual failure creates a chronic anxiety state that elevates blood pressure and impairs sleep.

The speakers acknowledge disagreement among themselves: one panelist noted that even healthy aging men show smaller, softer testicles and declining testosterone, while another emphasized that the slope can be dramatically steepened by obesity but should not cause severe hypogonadism without illness. The bidirectional relationship with obesity is key: gaining 10% body weight drops testosterone by ~85 ng/dL; gaining 15% drops it by ~270 ng/dL. Adipose tissue aromatizes testosterone to estrogen, and obesity increases leptin and inflammatory cytokines that suppress the hypothalamic-pituitary-testicular axis. The GLP-1 receptor agonists are now showing clinically significant and sustainable testosterone increases through weight loss, creating a new therapeutic intersection.

The prostate absorbs testosterone like a sponge up to the saturation point (~250 ng/dL). Once saturated, additional circulating testosterone does not affect prostate tissue. This means men with testosterone below 250 who start therapy will see a PSA rise as the prostate becomes saturated, but men starting above 250 will see no PSA change. The saturation point applies regardless of whether testosterone is delivered via gel or injection, making prostate cancer concern largely irrelevant for therapeutic testosterone. This mechanistic insight, combined with TRAVERSE trial data showing no increase in BPH or prostate cancer, should theoretically eliminate this prescribing barrier, yet the panel acknowledges that 'it takes a while to get out there.'

Testosterone cypionate/enanthate given as a single weekly intramuscular injection creates supraphysiologic peaks in the first 24-48 hours (levels >1000 ng/dL) followed by a decline toward trough. These transient spikes drive erythrocytosis (increased red blood cell mass) and may contribute to hypertension and mood lability. By dividing the total weekly dose into smaller, more frequent subcutaneous injections, the peak-to-trough ratio narrows dramatically, attenuating these side effects. The panel noted that patients prefer subcutaneous injections because they are less painful than intramuscular, and that 80% of the IM dose achieves equivalent blood levels when given subcutaneously — an important dose-adjustment caveat.